Clinical Trials for Other Solid Tumor

A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial is recruiting adult patients with advanced malignant solid tumors harboring KRAS G12C mutations who have exhausted standard therapies, aiming to evaluate the safety and maximum tolerated dose of HBI-2438, an investigational oral small molecule that irreversibly targets and inactivates KRAS G12C.

ClinicalTrials.gov ID: NCT05485974

A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with metastatic or unresectable solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and others, who have shown PD-L1 expression and have an ECOG performance status score of 0 or 1. It assesses the safety and efficacy of PF-08046054, a PD-L1-targeting antibody-drug conjugate, both as monotherapy and combined with pembrolizumab.

ClinicalTrials.gov ID: NCT05208762

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves participants aged 16 and older with advanced solid tumors and BRAF alterations, evaluating the safety and efficacy of PF-07799933, a brain-penetrant pan-mutant BRAF inhibitor, as a monotherapy and in combination with binimetinib and cetuximab.

ClinicalTrials.gov ID: NCT05355701

A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: The trial enrolls patients with advanced stage IIIB/IIIC or IV NSCLC with high PD-L1 expression (≥50%) to compare the efficacy and safety of cemiplimab monotherapy versus its combination with BNT116, an investigational mRNA cancer vaccine targeting tumor-associated antigens.

ClinicalTrials.gov ID: NCT05557591

A Phase I Open-label, Multi-dose, Dose Escalation and Dose Expansion Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adult patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion, uncommon, classical (Ex19del and L858R), and T790M drug-resistant mutations to evaluate the safety and efficacy of PLB1004, an irreversible EGFR tyrosine kinase inhibitor targeting these mutations while sparing wild-type EGFR.

ClinicalTrials.gov ID: NCT06046495

A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with untreated, advanced non-small cell lung cancer and high PD-L1 expression, evaluating cemiplimab combined with novel antibodies targeting TIM3, CD73, or NKG2A to assess safety, efficacy, and treatment outcomes.

ClinicalTrials.gov ID: NCT06162572

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates MDNA11, an IL-2 Superkine targeting the IL-2 beta receptor to enhance anti-tumor immunity, administered alone or with pembrolizumab, in adult patients with locally advanced or metastatic solid tumors. Eligible patients must have an ECOG performance status of 0 or 1 and adequate organ function.

ClinicalTrials.gov ID: NCT05086692

A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This study targets patients with stage IIIB-IV NSCLC who have progressed on previous anti-PD-1/PD-L1 therapy and platinum-based chemotherapy, testing JNJ-86974680, an A2a receptor antagonist, both alone and in combination with cetrelimab, a PD-1 inhibitor, and radiation therapy.

ClinicalTrials.gov ID: NCT06116786

An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects with Advanced or Metastatic Solid Tumor Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial targets adult patients with advanced or metastatic EGFR-expressing carcinomas such as NSCLC, CRC, and TNBC, who have exhausted other treatment options, using the investigational bispecific antibody JANX008 designed to activate in the tumor environment by targeting EGFR and CD3.

ClinicalTrials.gov ID: NCT05783622

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates the safety and efficacy of the combination of amivantamab and cetrelimab, a PD-1 inhibitor, in metastatic NSCLC patients who have progressed after standard treatment, with patients grouped by EGFR mutation status or PD-L1 expression.

ClinicalTrials.gov ID: NCT05908734